NASDAQ: AXSMAxsome Therapeutics Inc Stock
$109.92+2.68 (+2.5%)
Updated Apr 29, 2025
AXSM Price
$109.92
Fair Value Price
$14.63
Market Cap
$5.36B
52 Week Low
$64.11
52 Week High
$139.13
P/E
-18.35x
P/B
94.01x
P/S
10.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$385.69M
Earnings
-$287.22M
Gross Margin
91.4%
Operating Margin
-72.74%
Profit Margin
-74.5%
Debt to Equity
8.97
Operating Cash Flow
-$128M
Beta
0.95
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AXSM Overview
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AXSM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AXSM
Ranked#109 of 462
Ranked#109 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important AXSM news, forecast changes, insider trades & much more!
AXSM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AXSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AXSM ($109.92) is overvalued by 651.46% relative to our estimate of its Fair Value price of $14.63 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AXSM ($109.92) is not significantly undervalued (651.46%) relative to our estimate of its Fair Value price of $14.63 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AXSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AXSM due diligence checks available for Premium users.
Valuation
AXSM fair value
Fair Value of AXSM stock based on Discounted Cash Flow (DCF)
Price
$109.92
Fair Value
$14.63
Overvalued by
651.49%
AXSM ($109.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AXSM ($109.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AXSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AXSM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.35x
Industry
-158.75x
Market
29.19x
AXSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
94.01x
Industry
4.37x
AXSM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AXSM's financial health
Profit margin
Revenue
$118.8M
Net Income
-$74.9M
Profit Margin
-63.1%
AXSM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AXSM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$568.5M
Liabilities
$511.5M
Debt to equity
8.97
AXSM's short-term assets ($485.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AXSM's short-term assets ($485.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AXSM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AXSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.2M
Investing
-$30.0k
Financing
$14.2M
AXSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AXSM vs Biotech Stocks
Axsome Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.